Clinical trials: Parkinsonian Disorders
Parkinson's Disease
An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease
The purpose of the study is to estimate the pharmacodynamic effects of minzasolmin (UCB0599) on brain pathophysiology in Early-start versus Delayed-start participants originally diagnosed with new onset Parkinson's disease.
- Trial name
- NCT05543252
- Testing
- Minzasolmin (UCB0599)
- Where
- 96 sites in United States, Canada and 7 more
- Volunteers
- 428 people
- Sponsor
- UCB Biopharma SRL
Parkinson Disease
Nintendo WII and Exercises at Rehabilitation of Individuals With Parkinson's Disease
Patients with Parkinson's disease present motor dysfunctions such as stiffness, tremor, postural instability and bradykinesia, which leads to alterations of balance, necessitating specialized physiotherapeutic treatment.
- Trial name
- NCT03235284
- Testing
- Exercises, Nintendo Wii, Exercises and Nintendo Wii
- Where
- Brazil
- Volunteers
- 45 people
- Sponsor
- Federal University of Bahia
Parkinson's Disease, Idiopathic
A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD
The purpose of this study is to measure safety and efficacy of buntanetap/posiphen capsules compared with placebo capsules in participants with early PD. Study details include: The study duration will be up to 7-8 months.
- Trial name
- NCT05357989
- Testing
- buntanetap/posiphen
- Where
- 69 sites in United States, Germany and 4 more
- Volunteers
- 523 people
- Sponsor
- Annovis Bio Inc.
Parkinson Disease, Depression
Study of Antidepressants in Parkinson's Disease
The purpose of this study is to find out if two antidepressant medications, paroxetine and venlafaxine, can help control depression in Parkinson's disease, and if these medications affect the motor symptoms of Parkinson's disease…
- Trial name
- SAD-PD (NCT00086190)
- Testing
- paroxetine, venlafaxine
- Where
- 18 sites in United States, Canada and 1 more
- Volunteers
- 115 people
- Sponsor
- University of Rochester
Parkinson Disease, Neurodegenerative Diseases
Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175)
The purpose of this study is to assess the long term safety of SCH 420814 (preladenant) in participants with moderate to severe Parkinson's Disease who are taking an L-Dopa/dopa decarboxylase inhibitor and/or dopamine agonist.
- Conditions
- Parkinson Disease, Neurodegenerative Diseases, Central Nervous System Diseases, Movement Disorders
- Trial name
- NCT00537017
- Testing
- Preladenant, L-dopa, Other Parkinson's Disease treatments
- Volunteers
- 140 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson Disease, Cognitive Impairment
Low Frequency Deep Brain Stimulation of the Subthalamic Nucleus in Parkinson's Disease
Prospective trial of low frequency deep brain stimulation of the ventral subthalamic nucleus to improve cognitive performance in patients with advanced Parkinson's disease.
- Trial name
- NCT03204526
- Testing
- deep brain stimulation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, Davis
Motor OFF Episodes Associated With Parkinson's Disease
A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)
A study of an investigational drug to see how it affects the people with Parkinson's Disease complicated by motor fluctuations ("OFF" Episodes) compared to an approved drug used to treat people with Parkinson's Disease…
- Trial name
- NCT03391882
- Testing
- APL-130277, subcutaneous apomorphine
- Where
- 31 sites in Austria, France and 4 more
- Volunteers
- 113 people
- Sponsor
- Sumitomo Pharma America, Inc.
Parkinson Disease
Effectiveness and Implementation of the HiBalance Program in Clinical Practice
This effectiveness-implementation study is a part of the larger study BETA-PD (Balance, Elderly, Training and Activity in Parkinson's Disease), which has the long-term goal to reduce the risk of falling in people with Parkinson's…
- Trial name
- BETA-PD (NCT02727478)
- Testing
- HiBalance training program
- Where
- Sweden
- Volunteers
- 117 people
- Sponsor
- Karolinska Institutet
Parkinson Disease
Clinical Evaluation of the Infinity Deep Brain Stimulation System
The purpose of this post-market study is to characterize the clinical performance of the Infinity Deep Brain Stimulation (DBS) system, including the Implantable Pulse Generator (IPG), directional DBS leads, extensions, iPad…
- Trial name
- PROGRESS (NCT02989610)
- Testing
- Omnidirectional stimulation, Directional stimulation
- Where
- 41 sites in United States, Australia and 6 more
- Volunteers
- 234 people
- Sponsor
- Abbott Medical Devices
Parkinson Disease
Walking and mHealth to Increase Participation in Parkinson Disease
Identifying effective ways to improve function, slow decline and reduce disability is a high priority for people living with Parkinson disease and other chronic conditions.
- Trial name
- WHIPPD (NCT03517371)
- Testing
- mHealth delivered exercise program, Exercise only
- Where
- 2 sites in United States
- Volunteers
- 140 people
- Sponsor
- Boston University Charles River Campus
Parkinson Disease, Brain Stimulation
Cerebellar Transcranial Direct Current Stimulation in Parkinson's Disease
Parkinson's disease (PD) is the second most common neurodegenerative disorder and affects approximately 1 million people in the United States with total annual costs approaching 11 billion dollars.
- Conditions
- Parkinson Disease, Brain Stimulation, Cerebellum
- Trial name
- NCT04046055
- Testing
- Transcranial direct current stimulation at 2 mA, Transcranial direct current stimulation at 4 mA
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Thorsten Rudroff
Parkinson Disease, Parkinsons Disease With Dementia
Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease
Parkinson's disease (PD) is the second most common neurodegenerative disorder causing motor and non-motor symptoms. PD is characterized by death of dopaminergic (DA) neurons in the substantia nigra (SN) pars compacta and…
- Trial name
- PD Nilotinib (NCT02954978)
- Testing
- Nilotinib 150mg oral capsule [Tasigna], Nilotinib 300mg oral capsule [Tasigna]
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Georgetown University
Dystonia-Parkinsonism, Adult-Onset, Parkinson Disease
Unlocking Dystonia From Parkinson's Disease With Directional DBS Technology
This study occurs during five visits that are already scheduled as part of "Biomarkers to Guide Directional DBS for Parkinson's Disease" (ClinicalTrials.gov Identifier: NCT03353688).
- Trial name
- NCT03409120
- Testing
- Boston Scientific Vercise PC IPG with directional DBS lead
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of Alabama at Birmingham
Parkinson's Disease
Selegiline to Zelapar Switch Study in Parkinson Disease Patients
Parkinson's disease (PD) is a progressive neurodegenerative disease. Symptomatic therapy is primarily aimed at restoring dopamine function in the brain.
- Trial name
- NCT00640159
- Testing
- Zelapar
- Where
- 5 sites in United States
- Volunteers
- 48 people
- Sponsor
- Baylor College of Medicine
Parkinson Disease
N-Acetylcysteine for Neuroprotection in Parkinson's Disease
The overall objective of this developmental/exploratory study is to use noninvasive proton magnetic resonance spectroscopy (1H MRS) to assess (a) whether brain levels of the antioxidant glutathione (GSH) are decreased in vivo, as…
- Trial name
- NAC for PD (NCT01470027)
- Testing
- N-acetylcysteine
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
Parkinson Disease, Multiple System Atrophy
Treatment of Parkinson Disease and Multiple System Atrophy Using Intranasal Insulin.
Parkinson disease (PD) and multiple system atrophy (MSA) are progressive neurodegenerative disorders characterized by abnormal accumulation of α-synuclein.
- Trial name
- NCT02064166
- Testing
- Intranasal Insulin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Peter Novak
Parkinsons Disease
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease
This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early Parkinson's Disease (PD) who are on…
- Trial name
- PADOVA (NCT04777331)
- Testing
- Prasinezumab
- Where
- 110 sites in United States, Austria and 7 more
- Volunteers
- 586 people
- Sponsor
- Hoffmann-La Roche
Parkinson's Disease
Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy
The CELC200A2401 study has been designed in order to evaluate the hypothesis that administering the combination carbidopa/levodopa/entacapone at the time that levodopa therapy is initiated results in a decrease in the risk of the…
- Trial name
- STRIDE-PD (NCT00099268)
- Testing
- Carbidopa/levodopa/entacapone, Immediate release carbidopa/levodopa
- Where
- 73 sites in United States, Austria and 12 more
- Volunteers
- 747 people
- Sponsor
- Novartis Pharmaceuticals
Parkinson Disease
Deep Brain Stimulation (DBS) Frequency Effects on Gait in Parkinson's Disease(PD)
In this study the investigators will evaluate the effect of both low and high frequency Deep Brain stimulation of the subthalamic nucleus (STN) in Parkinson's patients who have noted a change in their walking.
- Trial name
- NCT00993291
- Testing
- Frequency change to 60 Hz, Frequency change to 130 Hz
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Vanderbilt University
Parkinson's Disease
Quantification of the Antidyskinetic Effect of Amantadine and Topiramate in Parkinson's Disease
Levodopa is the main drug treatment for Parkinson's disease. Levodopa can cause unwanted and uncontrolled movements called dyskinesias. A drug called amantadine can reduce these movements.
- Trial name
- NCT00794313
- Testing
- Amantadine 300 mg, Topiramate, Sugar Pill
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Oregon Health and Science University